Repository logo
 
Publication

High VEGFA expression Is associated with improved progression-free survival after Bevacizumab treatment in recurrent Glioblastoma

2023-04-07Journal article Open access
Simple item page
dc.contributor.authorAlves, Bárbara
dc.contributor.authorPeixoto, Joana
dc.contributor.authorMacedo, Sofia
dc.contributor.authorPinheiro, Jorge
dc.contributor.authorCarvalho, Bruno
dc.contributor.authorSoares, Paula
dc.contributor.authorLima, Jorge
dc.contributor.authorLima, Raquel T.
dc.date.accessioned2023-06-07T10:18:41Z
dc.date.available2023-06-07T10:18:41Z
dc.date.issued2023-04-07
dc.description.abstractGlioblastoma (GB) is a deadly tumor that demands for relevant biomarkers, particularly regarding patients’ response to treatment. MMP-2, MMP-9, VEGFA, and YKL40 are important molecules, given their implication in the infiltrative and angiogenic phenotype of GBs. The purpose of this study was to assess the relationship between the expression of MMP-2, MMP-9, VEGFA, and YKL40 in GB tissues and the patients’ response to temozolomide (first-line treatment) or bevacizumab (second-line treatment). Our results showed that increased VEGFA is significantly associated with an improved response to bevacizumab, while having no correlation with the response to temozolomide. Additionally, YKL40 expression may also be important regarding information about the extent of antiangiogenic treatment in GB patients.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationAlves, B., Peixoto, J., Macedo, S., Pinheiro, J., Carvalho, B., Soares, P., Lima, J., & Lima, R. T. (2023). High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma. Cancers, 15(8), 2196. https://doi.org/10.3390/cancers15082196pt_PT
dc.identifier.doi10.3390/cancers15082196pt_PT
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/10400.22/23087
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relation.publisherversionhttps://www.mdpi.com/2072-6694/15/8/2196pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectGlioblastomapt_PT
dc.subjectSecretomept_PT
dc.subjectBiomarkerspt_PT
dc.subjectImmunohistochemistrypt_PT
dc.subjectVEGFApt_PT
dc.subjectYKL40pt_PT
dc.subjectMMP-2pt_PT
dc.subjectMMP-9pt_PT
dc.titleHigh VEGFA expression Is associated with improved progression-free survival after Bevacizumab treatment in recurrent Glioblastomapt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage18pt_PT
oaire.citation.startPage1pt_PT
oaire.citation.titleCancerspt_PT
oaire.citation.volume15 (8)pt_PT
person.familyNameCouto Viana Alves
person.givenNameBárbara
person.identifier2824525
person.identifier.orcid0000-0003-1743-6022
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication9e287a17-721b-422f-a26b-b6e1437582c9
relation.isAuthorOfPublication.latestForDiscovery9e287a17-721b-422f-a26b-b6e1437582c9

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ART_Bárbara Alves 1.pdf
Size:
2.12 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESS - CQB - Artigos